OFEV, also known by its generic name nintedanib, is a prescription medication used primarily in the treatment of idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. It works by inhibiting multiple tyrosine kinases, proteins that play a significant role in the processes leading to fibrosis (scarring) and angiogenesis (formation of new blood vessels). By targeting these pathways, OFEV can slow the progression of lung fibrosis, helping to preserve lung function. Additionally, it is used in the management of chronic fibrosing interstitial lung diseases with a progressive phenotype and for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). OFEV is available in capsule form and is taken orally, usually twice a day with food. Like all medications, it can cause side effects, and its use must be closely monitored by a healthcare provider.